Jupiter Topco LLC Invests $233.22 Million in Surgery Partners, Inc. $SGRY

Jupiter Topco LLC bought a new position in Surgery Partners, Inc. (NASDAQ:SGRY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,882,155 shares of the company’s stock, valued at approximately $233,220,000. Jupiter Topco LLC owned about 0.11% of Surgery Partners as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Surgery Partners during the second quarter worth approximately $104,857,000. Pentwater Capital Management LP raised its stake in Surgery Partners by 66.9% during the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock worth $252,777,000 after purchasing an additional 4,681,000 shares during the period. UBS Group AG boosted its holdings in shares of Surgery Partners by 111.4% in the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock valued at $120,571,000 after purchasing an additional 4,113,052 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Surgery Partners in the 2nd quarter valued at $48,912,000. Finally, Goldman Sachs Group Inc. grew its stake in shares of Surgery Partners by 528.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock valued at $30,277,000 after buying an additional 1,647,714 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SGRY. Benchmark restated a “buy” rating on shares of Surgery Partners in a report on Tuesday, August 11th. Royal Bank Of Canada reduced their target price on Surgery Partners from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Surgery Partners in a research report on Friday, August 21st. TD Cowen upped their price target on Surgery Partners from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $17.00 price objective on shares of Surgery Partners in a report on Wednesday, May 6th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Surgery Partners has an average rating of “Moderate Buy” and a consensus price target of $19.45.

Surgery Partners Price Performance

Surgery Partners stock opened at $14.04 on Thursday. The firm has a fifty day moving average of $15.52 and a 200-day moving average of $14.39. Surgery Partners, Inc. has a 52-week low of $11.41 and a 52-week high of $23.44. The company has a quick ratio of 1.78, a current ratio of 1.95 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $1.84 billion, a P/E ratio of -20.06, a PEG ratio of 3.81 and a beta of 1.91.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Monday, August 10th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.04. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.88%. The business had revenue of $848.90 million for the quarter, compared to analyst estimates of $830.03 million. During the same quarter in the previous year, the business posted $0.17 EPS. The business’s quarterly revenue was up 2.7% on a year-over-year basis. As a group, analysts predict that Surgery Partners, Inc. will post 0.25 EPS for the current year.

Insider Buying and Selling

In related news, Director Teresa Deluca acquired 10,000 shares of Surgery Partners stock in a transaction on Tuesday, August 18th. The shares were bought at an average price of $14.35 per share, for a total transaction of $143,500.00. Following the completion of the purchase, the director directly owned 66,843 shares in the company, valued at $959,197.05. This trade represents a 17.59% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.00% of the stock is owned by company insiders.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.